

RESEARCH NEWS

RESEARCH NEWS

November 2, 2022 | Page 1 | 2

Fraunhofer at MEDICA/COMPAMED 2022

Reduced risk after cardiac surgery thanks to resorbable pacing leads

A team of researchers at the Fraunhofer Institute for Manufacturing Technology and Advanced Materials IFAM in Dresden is developing resorbable pacing leads that can significantly reduce risk factors after cardiac surgery. In collaboration with the Faculty of Medicine Carl Gustav Carus – TU Dresden, the institute's researchers are adopting this novel approach in the project "Resorbable Molybdenum Temporary Cardiac Electrodes," or "ReMoTe CarE" for short. The joint Fraunhofer booth (Hall 8a, Booth G10) at this year's COMPAMED trade show in Düsseldorf will showcase the very first demonstrators.

Postoperative cardiac arrhythmias are common after cardiac surgery. They are routinely treated with external pacemakers and temporary pacing leads that are prophylactically implanted at the time of surgery. This is inherently associated with several risks: Manually extracting modern stainless steel pacing leads can result in complications as the wires can, in some cases, resist extraction due to tissue in-growth. However, if the leads are cut and left in the body, there is the risk of infection and migration; in the case of the latter, revision surgery may be required.

In the ReMoTe CarE project, which is funded by the Else Kröner Fresenius Center for Digital Health in Dresden, researchers are investigating a completely new approach: In the future, bioresorbable leads that can be left in the body and then disappear by resorption after a defined period are expected to replace conventional leads. This approach is based on the use of the metal molybdenum (Mo), which offers several advantages. "Molybdenum degrades uniformly in the body, is biocompatible, and has high mechanical strength and electrical conductivity," explains Dr. Georg Pöhle, scientist at Fraunhofer IFAM in Dresden. For use in bioresorbable pacing leads, it is coated with resorbable biopolymers to electrically insulate the surrounding tissue.

Fraunhofer IFAM is testing and optimizing the mechanical, electrical and degradation properties of the materials used. The institute is also responsible for manufacturing the demonstrators – strands of fine metal wires that are coated with biopolymers. The demonstrators will be tested in preclinical studies at the Faculty of Medicine at TU Dresden later this year.

Contact

Roman Möhlmann | Fraunhofer-Gesellschaft, Munich, Germany | Science Communications | Tel. +49 89 1205-1333 | presse@zv.fraunhofer.de

Cornelia Müller | Fraunhofer Institute for Manufacturing Technology and Advanced Materials IFAM, Branch Lab Dresden | Phone +49 351 2537-555 | Winterbergstrasse 28 | 01277 Dresden, Germany | www.ifam-dd.fraunhofer.de | cornelia.mueller@ifam-dd.fraunhofer.de



The objective is to avoid the complications associated with non-resorbable pacing leads. This would not only provide great relief to patients but also significantly relieve the burden on both healthcare professionals and the healthcare system. Fraunhofer researchers will present the first demonstrators of the resorbable pacing leads at the joint Fraunhofer booth (Hall 8a, Booth G10) at the COMPAMED trade show in Düsseldorf from November 14 until 17, 2022.

November 2, 2022 || Page 2 | 2

RESEARCH NEWS

Fraunhofer IFAM in Dresden specializes in developments in the field of medical engineering. The institute also focuses on the mobility and energy technology fields of business.

More information:

https://www.ifam.fraunhofer.de/en/industries/Medical_Technology_Life_Sciences.html




Abb. 1 After the postoperative monitoring period, which lasts a few days, the resorbable pacing leads can remain in the body, where they slowly degrade.

© Fraunhofer IFAM Dresden




Abb. 2 Single (a, b) and double (c) coatings of different biopolymers applied to demonstrators of molybdenum pacing leads.

© Fraunhofer IFAM Dresden

The **Fraunhofer-Gesellschaft** based in Germany is the world's leading applied research organization. Prioritizing key future-relevant technologies and commercializing its findings in business and industry, it plays a major role in the innovation process. A trailblazer and trendsetter in innovative developments and research excellence, it is helping shape our society and our future. Founded in 1949, the Fraunhofer-Gesellschaft currently operates 76 institutes and research units throughout Germany. Over 30,000 employees, predominantly scientists and engineers, work with an annual research budget of €2.9 billion. Fraunhofer generates €2.5 billion of this from contract research.